Study Recruitment

Potential Benefits of Egrifta on the Brain

Status: Not Enrolling


The HNRP-CMCR at UCSD is conducting a study examining the potential benefits of Egrifta® on the brain.

What is Egrifta*:

  • Injectable prescription medication
  • Contains growth hormone-releasing factor
  • Reduces excess abdominal fat in HIV-infected individuals with lipodystrophy

In order to participate you must be*:

  • HIV positive with abdominal fat
  • Ages 40 and up
  • Currently on stable antiretroviral therapy
  • Wiling to do MRIs

Other information

  • Lab results (at no cost to you)
  • Monetary compensation
  • Free 6 months supply of Egrifta®

For further details regarding this study, or other studies, please call (619) 543-5000 and ask to speak with a recruiter.

*Not all individuals are eligible to participate.

All information collected is kept strictly confidential.

This study has been posted on Click here to access this posting.

Copyright ©2022 HIV Neurobehavioral Research Program | University of California, San Diego
For questions regarding this site, please contact the webmaster